Image source: Pixabay

Highlights

  • FY24 marks the eighth consecutive year of CUV’s revenue growth, with a 15% YoY increase to AUD 95.31 million
  • Over 17,000 SCENESSE® implants have been administered globally since its launch in 2016
  • 52-week high for CUV is AUD 18.20 and 52-week low is AUD 12.96

Clinuvel Pharmaceuticals Limited (ASX:CUV) is a Melbourne-based specialty pharmaceutical company focusing on developing and commercialising treatments for patients diagnosed with systemic, genetic, metabolic, and life-threatening acute disorders. SCENESSE® (afamelanotide 16mg) is CUV's leading therapy, pioneering drug development for repigmentation and photoprotection. Since its launch in 2016, SCENESSE® has driven impressive revenue growth, with a CAGR of 38%, showcasing the program's strong market performance and ongoing success. According to the latest data, more than 17,000 SCENESSE® implants have been administered globally through clinical and commercial channels.

The financial year 2024 (FY24) marks the eighth consecutive year of revenue growth for the company. The period saw a 15% YoY increase in revenue, interest, and other income to AUD 95.31 million, along with a 19% YoY rise in total assets to AUD 231.1 million. Cash flow from operations in FY24 grew marginally by 0.54% YoY to AUD 37.1 million.

Outlook

CLINUVEL is committed to developing new formulations and innovative products while broadening its focus to address additional medical indications. The company aims to integrate in-house manufacturing capabilities, maintain strong financial performance, and exercise disciplined capital deployment to maximise shareholder value. Through these efforts, CLINUVEL aspires to establish itself as a globally recognised and trusted household name in its field.

Share Performance of CUV

CUV shares closed 1.62% lower at AUD 13.40 apiece on 20 November 2024. Over the past year, CUV’s share price has dropped by almost 20%, and in the last three months, it has decreased by 1.25%.

52-week high for CUV is AUD 18.20, recorded on 4 December 2023, while 52-week low is AUD 12.96, recorded on 11 March 2024.

CUV Daily Technical Chart, Source: REFINITIV

Note 1: Past performance is neither an Indicator nor a guarantee of future performance.

Note 2: The reference date for all price data, and currency, is 20 November 2024. The reference data in this report has been partly sourced from REFINITIV.